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Can peripheral blood findings predict bone marrow infiltration in Hodgkin lymphoma?
Editor, The detection of bone marrow involvement (BMI) is important for the prognostication as well as planning of therapy in Hodgkin lymphoma (HL). Several studies have shown the superior sensitivity or negative predictive value (NPV) of fluorodeoxyglucose positron emission tomography (FDG-PET) in detecting BMI, [1] especially in patients with multifocal uptake, though a bone marrow biopsy (BMB) is needed to confirm the same. Despite several limitations, BMB is currently not recommended in the staging of HL if PET-CT is available. [2] However, in most of the resource-limited settings, the nonavailability of FDG-PET, its high cost, and the long-waiting periods even if it is available make it imperative to depend on BMB in the initial workup of HL. BMB is also useful in patients with focal or diffuse FDG-PET or with borderline SUV max values. In this background, we retrospectively evaluated the utility of peripheral blood findings in predicting BMI in patients with HL. A simplified scoring system was developed based on baseline complete blood count (CBC) and peripheral blood film (PBF) findings. The scoring system was tested prospectively in a cohort of 50 patients of HL who underwent bone marrow (BM) examination.
A retrospective analysis was performed in consecutive 250 HL patients who underwent BMB over a period of 32 months from January 2016 to August 2018. All cases of HL were staged by bilateral BMB, and the infiltration was reported on the basis of the presence of Reed Sternberg cells or mononuclear cells or equivalent cells reconfirmed by immunohistochemistry. The CBC, PBF, and BMB findings were collected from the laboratory records. A BMI was detected in 66 patients (26.4%). A comparison of various hematological parameters in cases with and without BMI is summarised in Table 1 . Univariate analysis using Man-Whitney test showed a significant difference between two groups in terms of hemoglobin (P = 0.000), platelet count (P = 0.004), total leukocyte count (P = 0.011), absolute lymphocyte count (P = 0.003), and absolute eosinophil count (P = 0.000). Chi-square test showed significant association of anemia (<11g/l) (P = 0.000), leukopenia (<4 × 10 6 /L) (P = 0.000), thrombocytopenia (<150 × 10 9 /L) (P = 0.000), neutropenia (<1.5 × 10 6 /L) (P = 0.000), lymphocytopenia (<1.5 × 10 6 /L) (P = 0.002) and the presence of immature cells (metamyelocytes, promyelocytes, blasts, and nucleated red cells) (P = 0.002) with the presence of BMI. The presence of anemia, thrombocytopenia, leucopenia, and immature cells in PBF was found to be independent predictors of BMI in multivariate analysis. By giving weightage to the predictive capacity (based on multivariate analysis) of each significant parameter, a formula was developed as follows based on a method described previously [3] : Z = 1 × immature cells (IC) + 1 × anaemia (A) + 2 × leukopenia (LP) + 2 × thrombocytopenia (TP); and the total score (Z) ranged from 0 to 6. The sensitivity, specificity, positive predictive value (PPV), and NPV of each score were calculated. A score of zero showed a NPV of 90.53%, while a score >3 showed specificity, PPV, and NPV of 97.28%, 73.68%, and 77.49%, respectively.
The scoring system was further tested prospectively in 50 consecutive patients of HL who underwent staging BM examination between September 2018 and February 2019. A total of 11 patients (22%) had BMI. The male-female ratio was 2.3:1. The age of the patients ranged from 14 to 82 years (median: 29 years). None of the patients with a score of zero (n = 21) showed BMI. Score >3 was seen only in one patient and he had BMI. Thus, the score of zero showed a NPV of 100%, while a score >3 showed a specificity, PPV, and NPV of 100%, 100%, and 76%, respectively, comparable to the original cohort reassuring the utility of the scoring system.
Compared to the reported frequency of BMI, which ranges from 2% to 32% and an average frequency of 13%, [4] our study shows a frequency of 26.4% possibly related to bilateral BMB rather than unilateral BMB and late presentation of patients related to their poor socio-economic status.
FDG-PET has been shown to have 96.9% sensitivity and 99.7% specificity in predicting BMI in HL. [5] Hence, BMB is not a replacement for FDG-PET in ideal situations. However, BMB continues to be a cost-effective and easily available procedure in the developing countries and will continue to be performed until the widespread availability of FDG-PET. In such a situation, it is imperative to develop alternative strategies to predict cases where BMB is unlikely to be positive and situations where BMB is highly likely to be positive. An efficient strategy should help to avoid painful BMB in both situations in the absence of FDG-PET studies. Vassilakopoulos et al. [3] evaluated 15 parameters of which six parameters were significantly related to BMI in multivariate analysis. The clinical predictive score developed based on these six parameters (B symptoms, anemia, clinical stage III/IV, leukocytes <6 × 10 9 /L, age ≥35 years, and inguinal/iliac involvement) were found to have a good NPV in excluding BMI. In our study, we included only CBC/PBF findings in developing a prediction system.
The peripheral blood findings in HL are quite varied possibly related to the complex endocrine effects of the cytokines released from tumor cells and their microenvironment. However, the current study shows that the presence of anemia, leukopenia, thrombocytopenia, and immature cells in PBF should be seen with caution as they could be indicators of BMI. The absence of any of these findings/ score 0 has a NPV of 91%, while a score >3 was found to have a specificity of 97.3% and PPV of 74%. The specificity of the cut-off values increases proportionately as the score increases with nearly 100% specificity and a PPV of nearly 80% if a cut off >5 is used. Overall, our scoring system is comparable to the previous study [3] in predicting BMI in patients with HL with the advantage of having only objective, easily available, and cost-effective parameters.
In future, the questions like whether patients with higher score need careful study of the BMB by deeper serial sections and immunohistochemistry to avoid the possibility of false-negative reporting; whether BMB can be safely excluded in patients with score zero or >5; and what is the utility of score in patients with homogeneous or borderline FDG-PET uptake can be studied prospectively. Despite being a retrospective analysis with unintentional or unavoidable selection bias, our study shows the utility of peripheral blood findings in identifying patients at risk of BMI in HL.
